Calcium phosphate nanoparticles successfully target and inhibit TRIB3 protein, overcoming a hurdle in lung cancer treatment
Background
Non-small cell lung cancer (NSCLC) is a common and aggressive malignancy, accounting for approximately 85% of all lung cancer patients. While targeted therapies against specific gene mutations are continuously being developed, many patients still face challenges due to drug resistance and metastasis. In particular, the protein tribbles pseudokinase 3 (TRIB3), which disrupts intracellular signaling and promotes the survival and metastasis of cancer cells, is known as a key factor that worsens prognosis. Clinical data support this, showing that patients with high levels of TRIB3 have relatively lower survival rates.
However, the development of targeted therapies that directly inhibit the TRIB3 protein has been hampered by technical limitations. This is because the protein structure makes it difficult to block the binding site with conventional compound-based drugs. Small interfering RNA (siRNA) technology, which inhibits gene expression itself, has emerged as an alternative, but it also faces the challenge of being easily degraded in the blood and difficult to penetrate cell membranes. To overcome these delivery limitations, calcium phosphate (CaP) nanoparticles, which are highly biocompatible and stable in serum, are emerging as a new alternative.
Key Findings
The research team, led by Professor Yinqiu Wu at Yangzhou University, developed calcium phosphate nanoparticles (NP RESULTS: In KP-1 cell experiments, NP CONCLUSION: This study is significant because it successfully blocks the TRIB3 protein, which has been extremely difficult to develop drugs for, using a safe, biocompatible mineral-based delivery system. In particular, by using a non-toxic calcium phosphate material, it effectively bypasses the problem of toxicity of the delivery system itself, which has been a major hurdle in gene therapy. This is expected to be a catalyst for the active introduction of gene silencing technology in NSCLC treatment in the future.
However, there are also clear challenges to be addressed before it can be applied to actual patients. It is unclear whether the excellent results confirmed in the preclinical stage will be reproduced in the complex immune system and tumor microenvironment of humans. In addition, it is necessary to minimize the off-target effects, which are slightly delivered to tissues other than the target tumor during intravenous administration. Furthermore, it is essential to standardize the process to maintain a uniform size of the nanoparticles during large-scale production.
BACKGROUND: TRIB3 is upregulated in non-small cell lung cancer (NSCLC) and associates with worse survival, yet targeted therapeutics remain lacking. Calcium phosphate (CaP) nanoparticles offer biocompatible, serum-stable delivery for siRNA therapy. Here, we developed CaP nanoparticles loading siRNA targeting TRIB3 (NP METHODS: NP RESULTS: TRIB3 was significantly upregulated in NSCLC tissues compared with normal lung tissues and was associated with poorer overall survival. NP CONCLUSION: NP
This study presents a personalized treatment scenario for NSCLC patients who are experiencing difficulties in treatment due to drug resistance and metastasis. If a patient's tumor tissue is analyzed in the clinic and TRIB3 protein overexpression is confirmed, NP CONCLUSION: This platform technology is expected to contribute to lowering the barriers to commercialization of gene therapy by facilitating large-scale production and storage. The fact that it can be expanded into a platform technology that regulates various solid tumor genes by improving the targeted delivery system is also a positive factor for the pharmaceutical industry as a whole.